Madrigal Pharmaceuticals, Inc.
corporate_fare Company Profile
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for MDGL at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Madrigal Gains Full Control Over Rezdiffra Patent Extensions from Roche
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$958.4M
Net Income
-$288.28M
Diluted EPS
-$12.85
Op. Cash Flow
-$189.55M
Free Cash Flow
-$190.02M
Operating Income
-$300.1M
Cash & Equivalents
$198.69M
Total Debt
$339.88M
Debt / Equity
0.56×
Net Margin
-30.1%
Shares Outstanding
22.84M sh
Source: 10-K · filed 2026-02-19 · accession 0001628280-26-009514
show_chartPrice Chart
Loading chart...
feed MDGL - Filings & News (Page 2)
MDGL
Jan 30, 2026, 5:00 PM EST
Price at Filing:
$489.31
Real-time Price:
$379.10
Change:
-$110.21 (-23%)
Market Cap:
$8.806B